Abstract
We analyzed over 40 years of bacteriological surveillance data to reveal a 4-fold increase in Group A streptococcal (GAS) meningitis in 2022 compared to the annual average of 1982-2021 (n=5/year). Already four GAS meningitis cases occurred in 2023 (until Feb 20th). Moreover, from May 2022 all GAS meningitis cases were caused by the Streptococcus pyogenes emm1 strains, of which 15 of the 19 (79%) belonged to the toxicogenic M1UK variant. Based on these observations, we urge clinicians to be vigilant regarding clinical sign of meningitis with invasive GAS infections, since this disease manifestation appears to have a higher than expected occurrence due to clonal replacement by the recently-emerged M1UK variant.
Introduction
Streptococcus pyogenes can cause a wide range of invasive infections, collectively referred to as invasive group A streptococcal (iGAS) infections. A rare but severe disease manifestation of iGAS is meningitis, which has an estimated incidence in adults of 0.2 per 1,000,000 persons per year 1,2. Several European countries as well as the United States have observed an unprecedented increase of iGAS infections in the past months, where the relative contribution of specific iGAS disease manifestations may differ from historic observations 3,4. Here we performed an epidemiological assessment of GAS meningitis cases based on over 40 years of national bacteriological surveillance data.
Methods
Microbiological surveillance and molecular epidemiology of all-cause bacterial meningitis, including S. pyogenes, is performed by the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM). For this study, we analyzed S. pyogenes isolates cultured from cerebrospinal fluid (CSF) between 1982-2023 (until Feb 20st), amounting to >40 years of consistent national data collection. Typing of S. pyogenes is based on sequence variation in 180 bp of the emm gene and is routinely performed by the NRLBM since 2013 according to the Centers of Disease Control and Prevention (CDC) protocol. Whole-genome sequencing (Illumina HiSeq) was performed on 19 emm1.0 isolates received between 2019 and 20th Dec 2022.
Results
Between 1982 and 2021, the NRLBM received a total of 216 S. pyogenes CSF isolates, with an annual average of five isolates (range 1-15). In contrast, 19 S. pyogenes CSF isolates were received in 2022, nearly 4-times higher than the 40-year annual average. Moreover, we already received four S. pyogenes CSF isolates until 20 Feb 2023.
Among the 48 CSF isolates from 2013-2021, 19 different emm (sub)types were distinguished, with emm1.0 ranking overall as the dominant emm-type at 35% (n=17; Figure 1), which is not uncommon among iGAS manifestations in Western countries5. However, from the 23 S. pyogenes CSF isolates that were received between 2022 and 20th Feb 2023, 20 (87%) isolates were identified as emm1.0 (Figure 1). We performed whole-genome sequencing on a smaller selection of emm1.0 isolates to distinguish whether they belonged to the recently-identified M1UK variant, which produces significantly higher levels of the SpeA superantigen compared to the previously circulating M1global strains6. Of the 19 emm1.0 isolates received between 2019 and 20th December 2022, 15 (79%) belonged to the M1UK lineage, with all isolates received from May 2022 onwards representing the M1UK variant. This suggests an extensive clonal replacement of S. pyogenes emm1.0 by this toxicogenic variant.
Number of received S. pyogenes CSF isolates with proportion of emm1.0, 2013-2023 (until Feb 20th).
Discussion
Our study only considered GAS meningitis patients based on S. pyogenes cultured from CSF, thereby excluding meningitis patients with only a positive S. pyogenes blood culture. This may have resulted in an underestimation of the overall national occurrence of GAS meningitis. Furthermore, submission bias of S. pyogenes isolates to the NRLBM may play a role, given the increased submission of isolates throughout 2022. Notwithstanding these study limitations, the strong overrepresentation of emm1.0 and particularly the toxicogenic M1UK variant among the received CSF isolates is unprecedented. We therefore urge clinicians to be vigilant regarding the occurrence of meningitis with iGAS, as this disease manifestation appears to have a higher than expected occurrence due to clonal replacement by the recently emerged M1UK variant.
Data Availability
The mentioned strains are available upon request to the authors.
Conflict of interest
NMvS declares fee for service and consultancy fees directly paid to the institution from MSD and GSK outside the submitted work. NMvS declared royalties related to a patent (WO 2013/020090 A3) on vaccine development against Streptococcus pyogenes (Vaxcyte; Licensee: University of California San Diego with NMvS as co-inventor). NMvS is a member of the Science advisory Board for the ItsME foundation (unpaid) and Rapua te me ngaro ka tau project (paid to institution; Project facilitating Strep A vaccine development for Aotearoa New Zealand). Other authors declare no conflict of interest.
Acknowledgements
The authors would like to thank Agaath Arends-van ‘t Klooster, Wendy Bril-Keijzers, Ilse de Beer-Schuurman, Jolein Pleijster, and Claudia Burger for their continued contributions as part of the NRLBM and the Dutch medical microbiology laboratories for sustained voluntary submission of S. pyogenes isolates.
